Bisphosphonate antifracture efficacy

Bone

Volumn 41, Issue 5 SUPPL. 1, 2007, Pages

  Adami, Silvano ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Alendronate; Bone mineral density; Ibandronate; Non vertebral fracture; Risedronate; Vertebral fracture

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PLACEBO; RISEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; POSTMENOPAUSE OSTEOPOROSIS; VERTEBRA FRACTURE;

EID: 35348837959     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.08.005     Document Type: Article

References (47)

1. Ross P. Clinical consequences of vertebral fractures. Am J Med 103 (1997) 30S-42S
2. Lips P., Cooper C., Agnusdei D., Caulin F., Egger P., Johnell O., et al. Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int 10 (1999) 150-160
3. Lips P. Invest in your bones: Quality of Life. Why prevent the first fracture?. International Osteoporosis Foundation (2003)
4. Center J.R., Nguyen T.V., Schneider D., Sambrook P.N., and Eisman J.A. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353 (1999) 878-882
5. Jalava T., Sarna S., Pylkkanen L., Mawer B., Kanis J.A., Selby P., et al. Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 18 (2003) 1254-1260
6. Naves B., az-Lopez J.B., Gomez C., Rodriguez-Rebollar A., Rodriguez-Garcia M., and Cannata-Andia J.B. The effects of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish population. Osteoporos Int 14 (2003) 520-524
7. Johnell O., Oden A., Caulin F., and Kanis J.A. Acute and long-term increase in fracture risk after hospitalization for vertebral fracture. Osteoporos Int 12 (2001) 207-214
8. Ismail A.A., O'Neill T.W., Cooper C., Finn J.D., Bhalla A.K., Cannata J.B., et al. Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 8 (1998) 291-297
9. Kado D.M., Browner W.S., Palermo L., Nevitt M.C., Genant H.K., and Cummings S.R. Vertebral fractures and mortality in older women: The Study of Osteoporotic Fractures. Arch Intern Med 159 (1999) 1215-1220
10. Johnell O., Kanis J.A., Oden A., Sernbo I., Redlund-Johnell I., Petterson C., et al. Mortality after osteoporotic fractures. Osteoporos Int 15 (2004) 38-42
11. Kanis J.A., Oden A., Johnell O., De Laet C., and Jonsson B. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15 (2004) 108-112
12. Melton III L.J. Who has osteoporosis? A conflict between clinical and public health perspectives. J Bone Miner Res 15 (2000) 2309-2314
13. Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am J Med 103 (1997) 20S-25S
14. Bone H.G., Adami S., Rizzoli R., Favus M., Ross P.D., Santora A., et al. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther 22 (2000) 15-28
15. Russell R.G., and Rogers M.J. Bisphosphonates: from the laboratory to the clinic and back again. Bone 25 (1999) 97-106
16. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., and Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100 (1997) 1475-1480
17. Eriksen E.F., Melsen F., Sod E., Barton I., and Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31 (2002) 620-625
18. Recker R.R. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int 15 (2004) 231-237
19. Wasnich R.D., and Miller P.D. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85 (2000) 231-236
20. Hochberg M.C., Greenspan S., Wasnich R.D., Miller P., Thompson D.E., and Ross P.D. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87 (2002) 1586-1592
21. Gatti D., and Adami S. BMD rishchio di frattura nei trial clinici. Bisfosfonati 5 (2004) 3-10
22. Black D.M., Arden N.K., Palermo L., Pearson J., and Cummings S.R. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J. Bone Miner. Res. 14 (1999) 821-828
23. Siris E.S., Brenneman S.K., Barrett-Connor E., Miller P.D., Sajjan S., Berger M.L., et al. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int 17 (2006) 565-574
24. van Staa T.P., Leufkens H.G., and Cooper C. Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos Int 13 (2002) 624-629
25. FDA. Guidelines for preclinical and clinical evaluation of agents in the prevention and treatment of postmenopausal osteoporosis. Tertiary Guidelines for preclinical and clinical evaluation of agents in the prevention and treatment of postmenopausal osteoporosis (1994)
26. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
27. Chesnut C.H., Silverman S., Andriano K., Genant H., Gimona A., Harris S., et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 109 (2000) 267-276
28. Chesnut C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 (2004) 1241-1249
29. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 (1999) 637-645
30. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282 (1999) 1344-1352
31. Reginster J.Y., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11 (2000) 83-91
32. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
33. Liberman U.A., Weiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333 (1995) 1437-1443
34. Felsenberg D., Papapoulos S.E., Miller P.D., Hughes C., and Schimmer R.C. Oral daily ibandronate rapidly and significantly reduces the risk of vertebral fractures of greater severity after 1, 2 and 3 years in postmenopausal women with osteoporosis. Bone 37 (2005) 651-654
35. Bauss F., and Schimmer R.C. Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. Therapeutics and Clinical Risk Management 2 (2006) 3-18
36. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344 (2001) 333-340
37. Brody B.A., Dickey N., Ellenberg S.S., Heaney R.P., Levine R.J., O'Brien R.L., et al. Is the use of placebo controls ethically permissible in clinical trials of agents intended to reduce fractures in osteoporosis?. J Bone Miner Res 18 (2003) 1105-1109
38. Temple R.J. Study designs in osteoporosis. J Bone Miner Res 18 (2003) 1129-1132
39. US Department of Health and Human Services. Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (2004)
40. Reginster J.Y., Abadie E., Delmas P., Rizzoli R., Dere W., der Auwera P., et al. Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men. Osteoporos Int 17 (2006) 1-7
41. Rizzoli R., Greenspan S.L., Bone III G., Schnitzer T.J., Watts N.B., Adami S., et al. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 17 (2002) 1988-1996
42. Schnitzer T., Bone H.G., Crepaldi G., Adami S., McClung M., Kiel D., et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 12 (2000) 1-12
43. Brown J.P., Kendler D.L., McClung M.R., Emkey R.D., Adachi J.D., Bolognese M.A., et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71 (2002) 103-111
44. Harris S.T., Watts N.B., Li Z., Chines A.A., Hanley D.A., and Brown J.P. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 20 (2004) 757-764
45. Reginster J.Y., Wilson K., Dumont E., Bonvoisin B., and Barrett J. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the Monthly Oral Pilot Study. J Clin Endocrinol Metab 90 (2005) 5018-5024
46. Miller P.D., McClung M., Macovei L., Stakkestad J.A., Luckey M., Bonvoisin B., et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20 (2005) 1315-1322
47. Reginster J.Y., Adami S., Lakatos P., Greenwald M., Stepan J.J., Silverman S.L., et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65 (2006) 654-661